Jonathan W. Simons
Impact in
- Cancer Research top 0.05%
- Cancer, Hypoxia, and Metabolism
- Oncology top 0.2%
- CAR-T cell therapy research
Papers in
-
- RNA Interference and Gene Delivery 9
- Renal and related cancers 7
-
- Cancer, Hypoxia, and Metabolism 26
- Cancer, Lipids, and Metabolism 9
- Co-authors
- Gregg L. Semenza (9 shared papers)Hua Zhong (6 shared papers)Erik Laughner (5 shared papers)Shuming Nie (6 shared papers)David Zagzag (4 shared papers)Hua Zhong (7 shared papers)Colleen F. Hanrahan (5 shared papers)Yun Xing (2 shared papers)
- Journals
- The Prostate (13 papers)Urology (8 papers)Cancer Research (5 papers)Cancer (4 papers)The Journal of Urology (4 papers)
- Partner nations
- United StatesNetherlandsIsrael
In The Last Decade
Jonathan W. Simons
122 papers receiving 18.4k citations
Jonathan W. Simons's Hit Papers
Peers
Comparison fields: 5 of 173
- Cancer Research 5.8k
- Oncology 4.5k
- Molecular Biology 9.0k
- Immunology 2.5k
- Genetics 2.7k
Countries citing papers authored by Jonathan W. Simons
This map shows the geographic impact of Jonathan W. Simons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan W. Simons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan W. Simons more than expected).
Fields of papers citing papers by Jonathan W. Simons
This network shows the impact of papers produced by Jonathan W. Simons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan W. Simons. The network helps show where Jonathan W. Simons may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan W. Simons, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Hit paper breakdown → | 1999 | 1976 |
| 2 | Identification of a Chromosome 18q Gene that Is Altered in Colorectal Cancers Hit paper breakdown → | 1990 | 1485 |
| 3 | Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Hit paper breakdown → | 2000 | 1281 |
| 4 | In vivo molecular and cellular imaging with quantum dots Hit paper breakdown → | 2004 | 1037 |
| 5 | Nanotechnology Applications in Cancer Hit paper breakdown → | 2007 | 928 |
| 6 | Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Hit paper breakdown → | 1990 | 811 |
| 7 | Phenotype of mice lacking functional Deleted in colorectal cancer (Dec) gene Hit paper breakdown → | 1997 | 657 |
| 8 | 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Hit paper breakdown → | 2003 | 637 |
| 9 | Expression of hypoxia-inducible factor 1? in brain tumors Hit paper breakdown → | 2000 | 539 |
| 10 | Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate Hit paper breakdown → | 1995 | 536 |
| 11 | Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis Hit paper breakdown → | 2001 | 525 |
| 12 | Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. | 1997 | 497 |
| 13 | 2007 | 439 | |
| 14 | 1999 | 409 | |
| 15 | Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. | 1999 | 399 |
| 16 | 2013 | 374 | |
| 17 | A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. | 2001 | 323 |
| 18 | 2008 | 316 | |
| 19 | Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. | 1996 | 296 |
| 20 | Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. | 2002 | 268 |
About Jonathan W. Simons
Jonathan W. Simons is a scholar working on Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, Oncology and Immunology, having authored 122 papers that have together received 19.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (26 papers), Cancer, Hypoxia, and Metabolism (26 papers), Immunotherapy and Immune Responses (18 papers), Virus-based gene therapy research (16 papers), Prostate Cancer Diagnosis and Treatment (10 papers), RNA Interference and Gene Delivery (9 papers), Cancer, Lipids, and Metabolism (9 papers) and Renal and related cancers (7 papers). The work is most often cited by research in Cancer Research (5.8k citations), Oncology (4.5k citations), Molecular Biology (9.0k citations), Immunology (2.5k citations) and Genetics (2.7k citations). Jonathan W. Simons has collaborated with scholars based in United States, Netherlands and Israel. Frequent co-authors include Gregg L. Semenza, Hua Zhong, Erik Laughner, Shuming Nie, David Zagzag, Hua Zhong, Colleen F. Hanrahan, Yun Xing, Angelo M. De Marzo and Fray F. Marshall. Their work appears in journals such as The Prostate, Urology, Cancer Research, Cancer and The Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.